| Vol. 8.02 – 21 January, 2022 |
| |
|
|
| Researchers found that interleukin-37b transgenic mice were highly susceptible to colitis-associated colorectal cancer and suffered from dramatically increased tumor burdens in the colon. [Signal Transduction and Targeted Therapy] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Genome-wide expression profiling, in vitro and in vivo experiments, revealed that timeless knockdown induced the activation of the epithelial-to-mesenchymal transition (EMT) program. [Cell Death & Differentiation] |
|
|
|
| Investigators developed a chronic-injury model in human colonoid monolayers by repeated rounds of air-liquid interface and submerged culture. [Cell Reports] |
|
|
|
| BEST4 is a member of the bestrophin protein family that plays a critical role in human intestinal epithelial cells. Scientists investigated the role and clinical significance of BEST4 in colorectal cancer. [Oncogene] |
|
|
|
| HERC3 was indicated to inhibit the migration, invasion and metastasis of colorectal cancer in vitro and in vivo through transwell assays, wound healing assays and vivo experiments. [Cell Death & Disease] |
|
|
|
| Scientists demonstrated that FTO, a key demethylase for RNA m6A modification, was up-regulated in gastric cancer tissues, especially in tissues with liver metastasis. [Cell Death & Disease] |
|
|
|
| The authors analyzed the expression of 373 miRNAs and 12 deregulated metabolic genes in murine duodenal polyps and non-polyp-derived organoids. [Oncogenesis] |
|
|
|
| Researchers showed that the expression of epididymal protein 3A (EDDM3A) was significantly upregulated in gastric cancer tissues and its upregulation correlated with poorer survival in patients with gastric cancer. [Oncogenesis] |
|
|
|
| Scientists developed DNA methylation markers that recapitulated the densities of tumor-infiltrating lymphocytes in gastric carcinoma. [Scientific Reports] |
|
|
|
| Researchers investigated the effects of cottonseed extracts on cell viability and gene expression in human colon cancer cells. [Scientific Reports] |
| |
|
|
|
| The authors review the current role for CTLA-4 inhibitors in early-stage resectable non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, and in metastatic NSCLC. [Current Oncology Reports] |
|
|
|
|
| Turning Point Therapeutics, Inc. announced that the company has received clearance from the FDA for the company’s IND application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer. [Turning Point Therapeutics, Inc.] |
|
|
|
|
|
|
|
| University of Oxford – Oxford, England, United Kingdom |
|
|
|
| University of North Dakota – Grand Forks, North Dakota, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
|